Abstract | The concept that viral sensing systems, via their ability to drive pro-inflammatory cytokine and interferon production, contribute to the development of autoimmune and autoinflammatory disease is supported by a wide range of clinical and experimental observations. Recently, the tripartite motif-containing proteins (TRIMs) have emerged as having key roles in antiviral immunity -either as viral restriction factors or as regulators of pathways downstream of viral RNA and DNA sensors, and the inflammasome. Given their involvement in these pathways, we propose that TRIM proteins contribute to the development and pathology of autoimmune and autoinflammatory conditions, thus making them potential novel targets for therapeutic manipulation.
1
. Several TRIM proteins -such as TRIM5α 2 , TRIM22 (REF. 3) and TRIM28 (also known as KAP1) 4 -have direct antiviral properties and can restrict several stages of the viral replication cycle. Furthermore, other TRIMs have been demonstrated to regulate signalling molecules downstream of pattern recognition receptors (PRRs) 5 . In this way, TRIMs contribute to the regulation of immune responses, including the production of type I interferons (IFNs) and pro-inflammatory cytokines such as interleukin-1β (IL-1β). With the accumulation of evidence identifying TRIMs as central regulators of IFN and IL-1β production, the idea that TRIMs contribute to the development of autoimmune and autoinflammatory diseases is gathering momentum.
Autoimmunity and autoinflammation constitute a broad spectrum of diseases that arise as a result of immune-mediated recognition of self (self DNA in the case of systemic lupus erythematosus (SLE) 6 , uric acid crystals in gout 7 or islet amyloid peptide in the case of type 2 diabetes 8 ). This leads to the overproduction of pro-inflammatory cytokines and type I IFNs. Inflammasomemediated IL-1β production is implicated in autoinflammatory conditions such as Crohn's disease, gout and type 2 diabetes 9, 10 , whereas the overproduction of type I IFNs is clearly associated with the development and pathology of many systemic autoimmune diseases, such as SLE and systemic sclerosis 11 .
With respect to what drives IFN-induced autoimmunity, evidence from molecular and genetic studies point to defects in viral detection sensors, downstream signalling pathways and the proteins that limit these responses as major contributors to the overproduction of type I IFNs 12, 13 . Virus-recognizing PRRs principally detect viral nucleic acid, and such sensors include Toll-like receptors (TLRs), cytoplasmic RIG-I-like receptors (RLRs), NOD-like receptor (NLR)-containing inflammasomes and the newly described HIN200 family of proteins, which function as intra cellular double-stranded DNA (dsDNA) receptors 14 . In the presence of pathogenic auto antibodies, nucleic acid sensors such as TLR7 and TLR9 can detect RNA 15 and DNA 16 released from damaged host cells.
This results in overproduction of type I IFNs and pro-inflammatory cytokines, and hence promotes the development of SLE. The emergence of TRIM family members as direct regulators of PRR signalling and inflammasome activation has focused our attention on their potential role in autoimmune and autoinflammatory disease.
In this Perspective, we discuss the emerging roles of specific TRIMs in the molecular mechanisms and pathways associated with inflammation and autoimmunity and, in this context, review the evidence that demonstrates a direct role for TRIMs. We focus primarily on TRIMs as regulators of the inflammasome and IFN production, and we discuss the hypothesis that defects in the expression or activity of key TRIMs may alter the normal cytokine balance and thus contribute to the development of certain autoimmune and autoinflammatory diseases.
TRIMs and autoimmunity TRIM family members typically contain an amino-terminal RING domain (which is critical for E3 ligase activity), a central B box and coiled-coil domain and a variable carboxy-terminal domain, which is important for substrate interaction 1 (see Supplementary information S1 (figure)). As E3 ubiquitin ligases, TRIMs ubiquitylate their substrates, which leads to degradation of the substrate, modulation of its function or alteration of its cellular localization. Altered expression of specific TRIMs (including TRIM16 and TRIM21) has been demonstrated in a number of autoimmune diseases. Increased TRIM16 expression was shown to positively correlate with hyperplasia of the synovium in a rat model of pristane-induced rheumatoid arthritis 17 , whereas TRIM21 expression is increased in cutaneous lupus erythematosus 18 . In addition, the expression of many TRIM family members is regulated by type I IFNs
, and this suggests that TRIM expression is altered in IFN-induced autoimmunity 19, 20 . Furthermore, direct evidence for an involvement of TRIMs in autoimmunity and autoinflammation (TABLE 1) has come from recent advances in our understanding of the function of TRIMs as regulators of immune signalling (via direct control of autoantigen levels) and as antiviral restriction factors.
TRIM21 and IFN induction. TRIM21 (also known as RO52) was until recently probably best known as a potent autoantigen associated with SLE and a range of other systemic autoimmune disorders 21 
. More recently, a number of independent studies have demonstrated that TRIM21 interacts with and regulates the stability of the IFN regulatory factor (IRF) family of transcription factors, essential transcription factors in the induction of cytokine expression [22] [23] [24] [25] . Although somewhat controversial, the cumulative data strongly suggest a crucial role for TRIM21 in regulating type I IFN and inflammatory cytokine production and potentially autoimmunity.
Two independent groups generated TRIM21-deficient mice, and both reported enhanced expression of pro-inflammatory cytokines in the absence of TRIM21, albeit with strikingly different phenotypes 26, 27 . In one study 26 , Trim21 was targeted in such a way as to delete the essential functional domains of TRIM21 -its central coiled-coil domain and the C-terminal PRY-SPRY domain -thus generating a non-functional protein. Immune cells from these mice overexpressed pro-inflammatory cytokines in response to TLR activation, and this resulted in tissue inflammation and systemic autoimmunity. At a molecular level, enhanced TLR7 and TLR9 responses were observed following recognition of nucleic acids, leading to overproduction of type I IFNs and pro-inflammatory cytokines, including the T helper 17 (T H 17) cell-promoting cytokine IL-23 (REF. 26) . Importantly, the authors demonstrated that genetic deletion of Il23 in TRIM21-deficient mice conferred protection from systemic autoimmune disease. This indicates that TRIM21 regulates IL-23 production in addition to type I IFNs and that the observed phenotype was driven by IL-23 and an enhanced T H 17-type response.
Although evidence from this report 26 and other in vitro studies 23, 25, 28 provides a mechanism whereby defective TRIM21 can contribute to the development of IFNmediated autoimmune disease, a separate Trim21-knockout model 27 , in which the full gene was disrupted, did not show any disease phenotype in response to intraperitoneal lipopolysaccharide challenge. In this study, although TLR-mediated induction of pro-inflammatory cytokines was enhanced in embryonic fibroblasts, no obvious functional defect in cytokine induction by immune cells was observed in these mice. However, impaired ubiquitylation of IRF3 and IRF8 was observed, consistent with previously reported in vitro studies 22, 23 . Based on the observed increase in expression of other TRIM family members in the absence of TRIM21, the authors concluded that the upregulation of other TRIM family members compensated for the loss of TRIM21. This suggests that multiple TRIMs combine to regulate pro-inflammatory cytokine production and thus guard against inflammatory and autoimmune disease 27 . Differences in the targeting strategies used to knock out Trim21 or in the environments used to house the mice have been suggested to underpin the varying phenotypes in the two studies 29, 30 . However, the most likely reason for the different results is the compensatory increase in the expression of other TRIM proteins that was observed by Yoshimi et al. 27 , as subsequent analysis revealed no such compensatory upregulation in the Trim21-knockout mice generated by Espinosa et al. 30 . In addition to the knockout studies, in vitro studies demonstrate a clear role for TRIM21 in regulating both IRF stability and the nuclear factor-κB (NF-κB) pathway, although the data are somewhat controversial in the case of IRF3 (see below).
Thus, on balance it would appear that, in addition to being a potent autoantigen, TRIM21 has an important role in regulating both pro-inflammatory and type I IFN responses downstream of TLRs. This suggests that defects in the expression or activity of TRIM21 may contribute to the pathogenic overproduction of IFNs observed in SLE. Subsequent studies in human immune cells will be essential to unravel the complexity surrounding TRIM21 and to understand its potential involvement in autoimmune disease. Like many other TRIM family members, TRIM21 is IFN-inducible, thereby ensuring tight control of IFN production and signalling via this negative feedback switch. Recently, TRIM21 has been shown to bind to internalized antibody-coated viruses via recognition of the Fc portion of the antibodies, and in doing so TRIM21 targets the complex for degradation 31 . This raises the intriguing possibility that the internalization of autoantibody complexes by cells may potentially result in altered TRIM21 function and could thus contribute to autoantibody-mediated pathology.
TRIM16 and regulation of autoantigen levels. TRIM16 (also known as EBBP) is an oestrogen-responsive gene that was initially described for its involvement in keratinocyte differentiation 32 and retinoid metabolism 33 . Recently, a study to identify candidate genes that confer invasive properties to synoviocytes in the rheumatoid arthritis pannus demonstrated a positive correlation between TRIM16 expression and hyperplasia of the synovium 17 . Intriguingly, TRIM16 has recently been shown to regulate the stability of vimentin in tumours 34 . Vimentin is a member of the intermediate filament family of proteins, and citrullinated vimentin is an autoantigen strongly associated with rheumatoid arthritis 35, 36 . The presence of autoantibodies
Box 1 | TRIM expression in the antiviral response and autoimmunity
A range of tripartite motif-containing proteins (TRIMs) are expressed in the cytosol and nucleus of most cell types, many of which localize to unidentified cellular compartments 95 . TRIM19 forms the mass bulk of nuclear bodies -distinct protein structures in the nucleus associated with a number of diverse functions, including the sequestration of transcription factors (such as nuclear factor-κB (NF-κB)).
Various TRIMs are induced by type I interferons (IFNs), including TRIM5α
96
, TRIM19 (REF. 97 ) and TRIM21 (REF. 98) . A study on primary human monocyte-derived macrophages reported that 16 TRIM mRNAs were upregulated following type I IFN-mediated stimulation, and all but two were also upregulated in stimulated peripheral blood lymphocytes 19, 20 . By contrast, stimulation of human primary immune cells with IFNγ upregulated a smaller subset of TRIMs, indicating the selective potential importance of these proteins in IFNγ signalling or responses. In addition, a subset of TRIMs (including TRIM16) is downregulated following type I IFN-or IFNγ-mediated stimulation. One might speculate that this response is self-protective, as it could limit the potential for autoimmunity. Finally, immune complex detection by the Fcγ receptor (FcγR) induces only two TRIMs (TRIM9 and TRIM54), neither of which are known to be important in immune function, and downregulates eight other TRIM mRNAs 20 , thus implicating these TRIMs as possible regulators of this pathway. The selective inducibility following type I or II IFN or FcγR signalling might allow the TRIM family to provide a multilayered antiviral immune response and simultaneously perform crucial immunoregulatory functions. Moreover, the increased production of type I IFNs that is associated with several autoimmune disorders (such as systemic lupus erythematosus), together with the intricate and diverse regulatory roles of IFN-inducible TRIMs, implicates certain members of the TRIM family as possible candidates for having physiological, and perhaps pathological, roles in autoimmunity.
against citrullinated vimentin is used as both a diagnostic and prognostic marker for rheumatoid arthritis 37 . Interestingly, vimentin has been reported to be released by activated macrophages in response to tumour necrosis factor (TNF)-mediated stimulation and has bactericidal effects by stimulating the production of reactive oxygen species (ROS), raising the possibility that vimentin acts as a danger signal in certain environments 38 . Therefore, it is possible that TRIM16 could have a role in regulating either TNF-mediated vimentin levels or TNF-mediated vimentin secretion during an innate immune response, potentially contributing to the pathology associated with rheumatoid arthritis.
Endogenous retroviruses and TRIM restriction. Strong links exist between viral infection, dysregulation of antiviral responses and the development of autoimmune conditions 39 . TRIMs have been
shown to act at almost every stage of the viral replication cycle in a screen that investigated a panel of TRIM family members for their involvement as viral restriction factors, thereby underlining their importance in antiviral immunity 5, 40 . Recently, a role has been uncovered for TRIMs as restriction factors for human endogenous retroviruses (HERVs), which constitute approximately 8% of the human genome. HERVs have been increasingly linked with autoimmunity owing to the ability of their gene products to act as superantigens or as drivers of autoantibody production (through cross-reactivity with HERV epitopes on self proteins), and as a result of their integration into immune response genes 41 . Elevated serum levels of the glycoprotein gp70 expressed by endogenous retroviruses, for example, are detectable in lupus-prone mice following stimulation of TLR7 or TLR9, thus linking endogenous retroviral protein expression and SLE 42, 43 .
Of the TRIM family members, TRIM5α is the best-studied retroviral restriction factor 44 . As such, TRIM5α recognizes the HIV viral capsid through its SPRY domain 45 , following which it multimerizes in cytoplasmic bodies and autoubiquitylates, and thereby destabilizes the retroviral capsid core, an activity absolutely dependent on its RING domain (which is encoded by exon 2). Recently, TRIM5α has been linked with the endogenous retrovirus HERV-Fc1 in the development of multiple sclerosis 46 , potentially suggesting a novel role for TRIM5α as a HERV restriction factor. In this study, single nucleotide polymorphisms (SNPs) in intron 1 of TRIM5α inversely correlated with the occurrence of multiple sclerosis. How these SNPs are associated with TRIM5α activity and potentially increase the risk of acquiring multiple sclerosis is still far from clear. One might speculate that the SNPs in intron 1 may affect correct expression of exon 2 of TRIM5 and thus affect protein activity. As a retroviral restriction factor, TRIM28 was originally identified as a silencer of Moloney murine leukaemia virus in embryonic stem cells 47, 48 . More recently, TRIM28 has been identified as a HERV restriction factor, recruiting a complex series of proteins that are required to methylate histones and thereby prevent HERV gene expression 4 . This suggests that defects in TRIM28 may result in enhanced expression of HERV transcripts, which are commonly associated with SLE and other autoimmune disorders.
Whether they act to regulate IFN levels or autoantigen availability or as antiviral restriction factors, links exist between antiviral TRIMs and autoimmune diseaseparticularly with respect to SLE, a disease driven by pathological production of IFNs and autoantibodies. As we explore further the links between cytokine production and TRIMs involved in regulating anti viral immune responses, potential roles for TRIMs in autoimmunity and autoinflammation are emerging. As with TRIM16, TRIM21 and TRIM5α, one can envisage how any alteration in the expression or function of other TRIM family members involved in these key pathways may increase autoimmune disease susceptibility.
TRIMs and IFN regulation
TRIMs are clearly emerging as key positive and negative regulators of virus-recognizing PRRs and type I IFN production 1, 5 (FIG. 1) .
Interestingly, the majority of TRIMs that control these pathways are SPRY domain-containing TRIMs (including TRIM5α, its murine orthologue (TRIM30), TRIM21 and TRIM27), suggesting that this subfamily of TRIMs has evolved to limit innate immune responses to viruses (see Supplementary information S2 (figure) ).
Regulation of nucleic acid detection.
Ubiquitylation has a strong role in both RNA-and DNA-sensing pathways, and a role for TRIMs as central regulators of these responses has been recently uncovered. TRIMs directly target both RNA-and DNA-sensing pathways. TRIM25 is one of the few PRY-SPRY domain-containing TRIMs that positively regulate pathogenrecognition pathways and hence IFN induction 49 . TRIM25 mediates K63-linked ubiquitylation of RIG-I, and this positively regulates the activity of RIG-I following viral infection 49 . In addition, RIG-I is activated by unanchored K63-linked polyubiquitin chains formed by TRIM25 (REF. 50 ). Recently, caspase 12 has been shown to positively regulate RIG-I-induced IFNβ production in response to West Nile virus infection by promoting TRIM25-mediated ubiquitylation of RIG-I, although the precise mechanism involved is still unknown 51 53 . It does so by binding to both IKKα-IKKβ and IKKε-TBK1 complexes, thus inhibiting NF-κB and IRF3, respectively, by an as yet unknown mechanism 53 . Although no known role for TRIM27 in autoimmunity has been described, genetic associations between TRIM27 and Crohn's disease, rheumatoid arthritis and type 1 diabetes have been uncovered from networkbased analysis of results from genome-wide association (GWA) studies 54 . IKKγ (also known as NEMO) is negatively regulated by TRIM40 (REF. 55 ). In this case, TRIM40 promotes conjugation of the ubiquitin-like protein NEDD8 to IKKγ in a process known as neddylation. Neddylation of IKKγ by TRIM40 inhibits NF-κB activation and thus contributes to the regulation of cell proliferation 55 . Recently, TRIM23 (also known as ARD1) has emerged as a positive regulator of IKKγ 56 . TRIM23 interacts with IKKγ and catalyses its ubiquitylation with K27-linked polyubiquitin chains, a modification crucial for IRF3 and NF-κB activation downstream of TLR3 and RIG-I 56 . In this study, the authors showed that TRIM23 interacts with TNFRassociated factor 3 (TRAF3) and speculated that TRIM23 may bridge TRAF3 and IKKγ. Interestingly, TRIM23 has also been shown to interact with TRAF6 and facilitate its K63-linked ubiquitylation, thereby positively regulating its activity 57 . Thus, TRIM23 has a substantial role in the pathway regulating IKKs.
Box 2 | TRIMs as autoantigens
The protective antibody response that accompanies viral infection often results in the appearance of autoantibodies against self proteins. Several mechanisms have been suggested to explain how these autoantibodies arise. Intracellular proteins, for example, can become visible to the immune system following the cell death or tissue damage that accompanies viral infection. Alternatively, post-translational modification of proteins in response to viral infection has been shown to increase the antigenicity of normally innocuous self proteins.
In addition, viral mimicry has been proposed as a key mechanism for generating autoantibodies. Here, viral epitopes cross react with epitopes found on normal self proteins and thus, during the course of an immune response to a virus, autoantibodies are generated. For example, autoantibodies against tripartite motif-containing protein 21 (TRIM21), an autoantigen associated with systemic lupus erythematosus (SLE), appear following Epstein-Barr virus infection as a result of altered membrane localization and enhanced expression of TRIM21 (REFS 99,100). TRIM68, an autoantigen in Sjogren's syndrome and SLE, is also exposed on the cell surface following viral infection 101 . Recently, autoantibodies against TRIM33 and the intracellular RNA sensor MDA5 have been identified in patients with autoimmune connective tissue disease 102 . Although the pathophysiology of autoantibodies is clearly established, it is currently unclear whether autoantibodies specific for TRIM family members have a role in disease pathogenesis other than as markers of disease. Potentially, internalization of autoantibodies by macrophages or dendritic cells may result in the inappropriate recognition of their target molecules, resulting in inhibition of the normal functions of these molecules or possibly their lysosomal degradation. In the case of autoantibodies specific for negative regulators of interferon (IFN) production (for example, TRIM21), this could have obvious consequences with respect to IFN production and disease pathogenesis. Figure 1 | TRIM-mediated regulation of TLR and RLR pathways. Tripartite motif-containing protein 5α (TRIM5α) (and its murine orthologue, TRIM30; not shown) is a negative regulator of Tolllike receptor (TLR) signalling and downregulates nuclear factor-κB (NF-κB) transcriptional activity via the degradation of TAK1-binding protein 2 (TAB2)-TAB3. TRIM40 negatively targets IκB kinase-γ (IKKγ) by promoting its conjugation to the ubiquitin-like protein NEDD8, and thus inhibits IKKγ activity and NF-κB activation. TRIM19 is also a direct negative regulator of this pathway and interferes with the binding of the NF-κB subunit p65 to its target promoters. Both TRIM21 and TRIM27 have been shown to interact with IKKs, repressing their activity and the subsequent production of pro-inflammatory cytokines. TRIM21 also polyubiquitylates IFN regulatory factor 3 (IRF3; not shown) and IRF7. In the case of IRF7, this induces its degradation and the repression of interferon (IFN) promoter activity. For IRF3, the data suggest that the role of TRIM21 in regulating its stability is more complicated, in that it stabilizes IRF3 during the initial stage of viral infection, and then promotes its degradation to limit IFN production and protect against overproduction. By contrast, TRIM21 ubiquitylates IRF8 to enhance cytokine expression in macrophages. TRIM25 positively regulates IFN induction by binding to retinoic acid-inducible gene I (RIG-I) and promoting its interaction with mitochondrial antiviral signalling protein (MAVS). TRIM56 can bind to the endoplasmic reticulum (ER)-associated adaptor protein stimulator of interferon genes (STING), which recruits TANK-binding kinase 1 (TBK1) for double-stranded DNA (dsDNA)-induced activation of IRF3 and production of IFNβ. TRIM23 interacts with TNFR-associated factor 3 (TRAF3) and ubiquitylates TRAF6 and IKKγ downstream of TLR3, TLR4 and RIG-I, resulting in NF-κB and IRF3 pathway activation. Finally, following caspase 1-mediated cleavage, the pyrin domain of TRIM20 is released and interacts with the NF-κB p65 subunit to promote NF-κB activity. MAL, MYD88 adaptor-like protein (also known as TIRAP); MYD88, myeloid differentiation primary response protein 88; RLR, RIG-I-like receptor; TRAM, TRIF-related adaptor molecule; TRIF, TIR domain-containing adaptor protein inducing IFNβ.
Given the important role TRIMs play in regulating IKK activity, alterations in TRIM expression or function could potentially have a profound effect on both cytokine production and inflammatory and autoimmune disease.
Regulation of transcriptional responses.
Both GWA studies and evidence from genetically modified mice have linked the dysregulation of several transcription factors with autoimmune diseases. Signal transducer and activator of transcription 1 (STAT1)-deficient mice, for example, are highly susceptible to experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein (MOG) 58, 59 , and polymorphisms in IRF5 (REFS 60, 61) and IRF7 (REF. 62) have been linked to the development of SLE. With respect to IRF5, an association between increased IRF5 expression and the IRF5 risk haplotype has been demonstrated in patients with SLE 63 . In this study, the authors identified an IRF5 isoform with a shorter 3ʹ untranslated region and increased transcript and protein expression levels in patients with SLE 63 ; this could potentially result in enhanced downstream effects on pro-inflammatory gene expression. Interestingly, this study also demonstrated enhanced levels and activity of spliceosome components in patients with SLE, suggesting that this contributes to the significant upregulation of alternative splicing seen in primary blood cells of patients with SLE 63 . A role for TRIMs as regulators of transcription factor activity, localization and stability is emerging. TRIM28, a potent viral restriction factor, also binds and negatively regulates STAT1 and STAT3 (REFS 64, 65) . By contrast, TRIM21 targets and regulates the stability of several members of the IRF family [22] [23] [24] [25] 28 . IRF8, for example, is positively regulated by TRIM21-mediated ubiquitylation following IFNγ-and TLR-mediated stimulation of mouse macrophages 22 . However, most importantly with respect to IFN-driven autoimmunity, TRIM21 has been shown in some studies to promote the degradation of IRF3 and IRF7 (key drivers of IFN expression), thus limiting type I IFN production downstream of pathogen recognition 23, 25, 28 . However, TRIM21 has also been demonstrated to stabilize IRF3 expression levels by interfering with the interaction between IRF3 and the peptidylprolyl cis-trans isomerase PIN1, thereby preventing the degradation of IRF3 (REF. 24 ). In doing so, TRIM21 was shown to positively regulate IRF3 activity in response to Inflammasome activation results in the processing and activation of caspase 1 and the production of the pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-18. The PRY-SPRY domain of tripartite motif-containing protein 16 (TRIM16) interacts with both caspase 1 and NOD-, LRR-and pyrin domaincontaining 1 (NLRP1), resulting in enhanced IL-1β secretion. TRIM16 also promotes the secretion of mature IL-1β via an undefined pathway, an effect that is dependent on its B box domain. Pro-inflammatory stimuli result in the release of an autoinhibitory interaction between the pyrin domain (PYD) of TRIM20 and its B box domain. Once activated, the PYD of TRIM20 interacts with the adaptor protein ASC (a crucial component of the inflammasome complex), which oligomerizes in the cytoplasm following interaction with the TRIM20 PYD and facilitates the formation of the multiprotein complex. Conversely, the SPRY domain of TRIM20 has been shown to interact with and inhibit NLRP3, caspase 1 and pro-IL-1β processing. Another negative regulator is TRIM30, which inhibits NLRP3 activity via an unknown mechanism that involves the production of reactive oxygen species.
Sendai virus infection. These conflicting findings suggest that the activity of TRIM21 is complex; it is perhaps involved in the stabilization of IRF3 expression during the initial response to a viral challenge but, later in the immune response, TRIM21 activity might switch (possibly through the recruitment of additional factors) to downregulate IFN production via the degradation of IRF3 and IRF7. In addition, in vitro studies have shown that TRIM21 binds to IRF5, although whether this activity is functionally relevant in vivo is not yet known 26, 28 . Interestingly, studies have demonstrated that TRIM21 targets IKKβ (a component of the NF-κB pathway) for monoubiquitylation 66 and subsequent targeting to autophagosomes, where it is destroyed 67 . Thus, on balance and taking into account the data from both strains of TRIM21-deficient mice, it would appear that the role of TRIM21 in regulating transcriptional responses is inhibitory and may ultimately be dependent on the type of stimulus received.
TRIM19, which is more commonly known as the promyelocytic leukaemia (PML) protein, is a tumour suppressor that functions to organize PML nuclear bodies 68 . Although lacking a SPRY and PRY domain in its C terminus, TRIM19 regulates several transcription factors, including STAT1 (REF. 69 ) and NF-κB 70, 71 , albeit with opposing effects. TRIM19 inhibits the expression of NF-κB-dependent genes by binding to the NF-κB p65 subunit and physically interfering with its binding to promoters 70, 71 . By contrast, in response to IFNγ, TRIM19 enhances the tyrosine phosphorylation of STAT1 and thus its activity 69 . In addition, IFNγ-mediated stimulation induces an association between TRIM19 and PML zinc finger protein (PLZF; also known as ZBTB16) and promotes the recruitment of histone deacetylase 1 (HDAC1). This leads to enhanced IFNγ-mediated antiviral gene expression as a result of enhanced activity of the STAT1-containing IFN-stimulated gene factor 3 (ISGF3) complex 72 . Although PLZF is normally a transcriptional corepressor, this study showed that phosphorylation of PLZF aids recruitment of HDAC1 and promotes the switch from transcriptional repressor to transcriptional activator. Interestingly, autoantibodies specific for TRIM19 and other nuclear body proteins have been detected in patients with primary biliary cirrhosis 73 (an autoimmune disease of the liver), indicating that these proteins are potentially overexpressed in this condition, probably as a result of increased IFNγ levels in patients 74 .
TRIM8 might also have an indirect role in regulating type I IFN production by virtue of its effects on STAT3, which attenuates the type I IFN response 75, 76 . TRIM8 has been demonstrated to regulate STAT3 signalling both by interacting with heat shock protein 90β (HSP90β) 75 and by degrading protein inhibitor of activated STAT3 (PIAS3) 76 . Thus, TRIMs act at many levels of the PRR signalling pathways that regulate proinflammatory cytokine and IFN production in response to viruses, from nucleic acid detection through to the regulation of transcriptional responses. In doing so, they contribute to the maintenance of a healthy cytokine balance, thus protecting against exaggerated responses. One would predict that any alteration in the function or levels of these TRIMs may have profound effects on immune homeostasis, and could therefore provoke autoimmune pathology.
Inflammasome regulation by TRIMs
Excessive inflammasome activation has been associated with inflammatory diseases, including Crohn's disease 9 , gout 7 and familial Mediterranean fever (FMF) 77 , and also has a role in autoimmune diseases such as rheumatoid arthritis 78 . So far, the role of TRIMs in regulating inflammasome activity has been largely underappreciated, but emerging evidence suggests a crucial role for these proteins in regulating both inflammasome assembly and IL-1β secretion (FIG. 2) . TRIM20. FMF is an autosomal recessive disorder characterized by periodic bouts of fever and inflammation, representing a lack of regulatory control on inflammasome activity and hence IL-1β production 77 . The gene responsible for this disorder (MEFV) encodes TRIM20 (also known as pyrin), a RING-less TRIM family member. Several groups have shown that TRIM20 interacts with the inflammasome adaptor molecule ASC via a homotypic interaction involving its N-terminal pyrin domain (PYD) [79] [80] [81] . However, although Yu et al. suggest that this interaction positively regulates inflammasome activity 82 , other studies have shown this interaction to be inhibitory 81 . These seemingly contradictory reports may now be explained in light of a recent study that investigated the interaction between TRIM20 and PSTPIP1 (proline-serinethreonine phosphatase-interacting protein 1) 80 . This study indicates that TRIM20 exists as a homotrimer in quiescent cells and that association with PSTPIP1 releases an autoinhibitory interaction between the N-terminal PYD of TRIM20 and its central B box. This frees the PYD of TRIM20 to facilitate interaction with ASC and thus promote activation of the inflammasome 80 . Although the endogenous stimulus that drives the interaction between TRIM20 and PSTPIP1 was not identified, this study indicates that full-length TRIM20 represses inflammasome activation until the appropriate signal is received to trigger the release of its PYD, allowing it to promote inflammasome activity.
The stimulatory properties of the PYD of TRIM20 are also demonstrated by the fact that this domain, once released following cleavage of TRIM20 by caspase 1, interacts with the NF-κB p65 subunit to promote NF-κB activity at target promoters 83 . By contrast, the SPRY domain of TRIM20 is inhibitory and negatively regulates inflammasome activity by binding to caspase 1, pro-IL-1β 81, 84 and NOD-, LRR-and pyrin domain-containing 3 (NLRP3) 81 . Indeed, disease-associated mutations in TRIM20 are clustered within the C-terminal domain and act to reduce inhibitory interactions with caspase 1, thus providing a molecular explanation for the link between mutations in TRIM20 and enhanced IL-1β secretion and autoinflammatory disease 84 . Interestingly, the known mutations in TRIM20 that cause FMF (M694A and V726A) have recently been described as risk alleles for the development of multiple sclerosis and for exacerbated morbidity in patients with this disease 85 . Specifically, these alleles are overrepresented in cohorts of patients with multiple sclerosis, and the frequency of multiple sclerosis in patients with FMF is twice that normally observed 86 . Although somewhat controversial, a role for IL-1β in the pathogenesis of multiple sclerosis has been suggested 87 , indicating that TRIM20 may be functionally important in FMF-associated cases of multiple sclerosis. Additional links between TRIM20 and autoinflammation exist. For example, mutations in PSTPIP1 that alter its interaction with TRIM20 have been linked to the development of the autoinflammatory condition PAPA syndrome (pyogenic arthritis, pyoderma gangrenosum and acne syndrome) 88 .
TRIM16.
Recently, a role for TRIM16 in regulating the secretion of IL-1β has been reported 89 . Like TRIM20, TRIM16 is a RINGless TRIM family member that has been shown to interact with the inflammasome components caspase 1 and NLRP1 via its C-terminal PRY-SPRY domain. TRIM16 also binds pro-IL-1β directly via its PRY-SPRY domain and promotes IL-1β secretion by an undefined pathway that involves the B box of TRIM16 (REF. 89 ). Given the positive correlation between TRIM16 expression and invasive properties of rheumatoid arthritis synoviocytes, it would be interesting to test whether altered TRIM16 regulation of IL-1β secretion has a role in this pathology.
TRIM30.
Murine TRIM30 is a RING domaincontaining TRIM and has been recently suggested to be important for regulating IL-1β production in mice 90 . Hu et al. demonstrated that TRIM30 regulates the inflammasome by inhibiting NLRP3 function and hence IL-1β secretion via an unknown mechanism involving ROS production 90 . Given the recent findings that ROS drive inflammasome formation and hence activation 91 , the precise mechanism by which TRIM30 mediates its effects on this process will be revealing. Additional roles for murine TRIM30 and its human orthologue, TRIM5α, in regulating inflammation have emerged recently, centring around their ability to regulate the activation of NF-κB 92, 93 . TRIM5α has been shown to interact with and ubiquitylate TAK1-binding protein 2 (TAB2) 93 , or the TAB2-TAB3 complex in the case of TRIM30 (REF. 92 ), and this results in the degradation of TAB2, disruption of the TRAF6-TAK1-TAB complex and inactivation of NF-κB-dependent pathways. Recently, however, TRIM5α has been suggested to act as a PRR for the retroviral capsid of HIV, thus promoting innate immune signalling and NF-κB activity 94 . Therefore, TRIM5α may potentially regulate inflammatory pathways differently depending on the stimuli given or the insult perceived by the cell. As TRIM5α is implicated as a protective factor for multiple sclerosis, unravelling the different functions of TRIM5α in inflammatory pathways will be crucial in order to fully understand its potential role in disease.
In addition to the role of inflammasome hyperactivation in the pathogenesis of a range of autoinflammatory disorders (including FMF and Muckle-Wells syndrome), the NLRP3 inflammasome has recently been shown to be important in regulating IL-1β production by mouse macrophages in response to islet amyloid polypeptide (IAPP) 8 . IAPP is a peptide produced by β-cells of the pancreas and found in amyloid deposits in patients with type 2 diabetes, and thus it potentially links the inflammasome and IL-1β production with the progression and pathogenesis of type 2 diabetes. This raises the possibility that TRIM family members (specifically TRIM20, TRIM16 and TRIM30) could be important contributors to the pathogenesis of this disease through the regulation of IL-1β production.
Future perspectives
From the evidence presented in this article, it is clear that TRIMs, as positive regulators of IFN production and inflammasome activity, have the potential to become foes in autoimmune or inflammatory disease should their activity or expression be enhanced. For example, both TRIM16 and TRIM20 positively regulate inflammasome activity and, in the case of TRIM20, activating mutations are linked with both multiple sclerosis and inflammatory disease. This is not surprising given the role that inflammatory cytokines have in most autoimmune and inflammatory conditions, and it strongly indicates that TRIMs that positively regulate inflammasome activity and hence IL-1β production have the potential (if hyperactivated or overexpressed) to drive the progression and pathology of conditions such as rheumatoid arthritis.
By contrast, TRIMs that negatively regulate either the production of IFNs or inflammasome activity might be friends in certain diseases, protecting against the overproduction of pathogenic cytokines and hence the development of autoimmune and autoinflammatory conditions. However, loss of function or expression of these protective TRIMs would also be expected to result in the development of disease, as has been suggested for TRIM21. TRIM5α may have a protective role against the development of autoimmune disorders such as multiple sclerosis via its ability to detect retroviruses or by potentially negatively regulating inflammasome activity. Thus, IFN-induced upregulation of TRIM5α (and potentially other TRIMs) would positively contribute to the management of autoimmune diseases such as multiple sclerosis, thus helping to explain in part the protective effects of IFNs on this disease.
It is therefore imperative that we elucidate the exact contribution of TRIMs in inflammatory signalling pathways and define their precise role as potential regulators of autoimmune progression. A detailed understanding of how the activity of the PRY-SPRY domain-containing TRIMs in particular is regulated and whether they are amenable to rational drug design will potentially enable us to manipulate their activity for the treatment of disease in the future. 
